The company's business results for the year 2025.
EIPICO Pharmaceuticals: The Crown Jewel of ACDIMA - Strategic Pillar for the State in Providing Medicine to Citizens - announced its business results for the year 2025, confirming with figures its leadership in medicine provision and its pioneering role in deepening and localizing the pharmaceutical and Active Pharmaceutical Ingredients industry in Egypt.
Coinciding with the publication of the IQVIA report for January 2026, which highlights a promising start for EIPICO this year.
The company secured first place in pharmacy sales in the Egyptian market by unit-wise.
For the first time in the company's history, it achieved second place among all pharmaceutical companies in Egypt by value for January 2026.
EIPICO's ophthalmic products also ranked No.1, being the top-selling by unit-wise, 30% Ms.
The consolidated financial statements for EIPICO for the year 2025 indicated its success in achieving its targets.
Production volume reached 10.812 billion EGP, a growth rate of 28% compared to 2024.
Total sales reached 9.441 billion EGP, achieving a growth of 28.1%.
Exports reached 2.967 billion EGP, an increase of 18.7% and has remained at the top of Egyptian pharmaceuticals export for years, accounting for 26% of total Egyptian exports and exporting to 67 countries.
Net profit after tax reached 1.458 billion EGP, achieving a growth of 33% compared to 2024.
The company's Board of Directors report, disclosed on the Egyptian Exchange platform, noted that EIPICO is moving at an accelerated pace toward implementing its strategic projects and development plans.
Total investments during 2025 reached 1.257 billion EGP.This includes 557.71 million EGP in investments for company expansions and development. Additionally, 734 million EGP in investments were injected into the EIPICO 3 plant in the same year.
In this context, the Board of Directors' report indicates that during the past year, the operating license for the EIPICO 3 factory was received from both the Egyptian Drug Authority and the Industrial Development Authority, and the first biological product of the factory, ADALIMAB, was launched.
The factory will start operation soon, to be the first factory in Egypt and the Middle East to produce biologicals and biosimilars, starting from the cell reaching the final product. This factory constitutes a pivotal turning point in deepening and localizing biologicals and biosimilars industry in Egypt, supporting the state's efforts and assisting citizens by providing a permanent supply of these products with international quality and reducing imports. Furthermore, it aims at building a new generation of Egyptian youth capable of dealing with the highest international levels in the technology and science of the pharmaceutical industry.
On another hand, the plans set for implementing the Arab Company for Active Pharmaceutical Ingredients (ARAB API) are proceeding according to the timetable. The project land, with an area of 96.8 thousand square meters, was received in the Economic Zone at Ain Sokhna. EIPICO's contribution to its capital amounts to about 33% of the company's total capital.
It will be the first multi-purpose factory in Egypt and the Middle East for the production of Dr.Ahmed Kelani, Chairman of Arab API, confirmed that Egypt Active Pharmaceutical Ingredients, to enhance drug security in Egypt through the sustainable availability of important Active Pharmaceutical Ingredients and reducing the import invoice for Active Pharmaceutical Ingredients.
All studies have been completed, and the environmental impact study session for the project was successfully held in the presence of representatives of all concerned authorities. In mid-January of this year, the foundation stone for the project was laid, marking the beginning of the construction phases.
The company's Board of Directors' report also refers to the company's keenness to develop its product portfolio to provide more medicines to citizens and to enhance its competitive position in the market. Last year, EIPICO injected 25 new products into the market, including 4 ophthalmic products, and injected 70.9 million EGP into product development research.